Many industry payments to NHS organisations are unexplained and disclosure figures can’t be trusted. This raises questions ...

Deal volumes for pharmaceutical deals were lower in 2023 than they were 10 years ago and have been lower, on average, than ...

Tyr Pharma has a pivotal year ahead with key readouts for Efzofitimod, potentially opening a huge market. Find out why ATYR ...

At CPHI Europe, an expert discussed the significance of implementing effective AI strategies to improve nutraceutical ...

Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it ...

Walgreens Boots Alliance is significantly undervalued, trading at low P/E multiples and a 44% discount to its book value. See ...

The latest update on Thursday morning shows Cencora shares down by 0.0%, trading at $234.52. At this price, Collis's 21,509 ...

Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative ...

Criticism of PBMs has grown amid federal actions and reform efforts, but Georgia Gov. Brian Kemp vetoed a bill aiding ...

The Signals Research Suite is the first fully integrated SaaS platform. This solution is ideal for scientists working on new drug modalities or who want to expand the power of Signals Notebook across ...

Malaysia's pharmaceutical market is currently worth $3 billion, more than three times the size of the market in Singapore. Malaysia's market for drugs is growing rapidly, at average annual rates ...